These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension.
    Author: Frick MH, McGibney D, Tyler HM.
    Journal: J Cardiovasc Pharmacol; 1988; 12 Suppl 7():S76-8. PubMed ID: 2467135.
    Abstract:
    A multicenter, placebo-controlled trial assessed the antihypertensive efficacy and safety of different doses of amlodipine in patients with mild to moderate hypertension. Amlodipine was administered once daily in doses of 1.25-2.5 mg (low-dose group), 2.5-5.0 mg (medium-dose group), and 5.0-10.0 mg (high-dose group) during 8 weeks; doses were titrated within each group after 4 weeks of double-blind treatment if normotension or "target" blood pressures had not been achieved. After 4 weeks, supine systolic and diastolic blood pressures were significantly reduced in the medium and high-dose groups compared with placebo; standing blood pressures were significantly reduced only in the high-dose group. After 8 weeks of treatment, all blood pressures were significantly reduced except standing systolic and diastolic blood pressures in the low-dose group. There was a low incidence of side effects, which were generally mild to moderate in intensity, and there were no clinically significant effects on pulse rate, electrocardiogram, or body weight. Amlodipine produces a dose-related reduction in blood pressures with once-daily dosing, 2.5 mg being the minimum effective dose, and is well tolerated.
    [Abstract] [Full Text] [Related] [New Search]